Advertisement

Topics

Biocon Company Profile

15:30 EDT 21st September 2018 | BioPortfolio

Biocon is India's leading biotechnology enterprise. Over the past 25 years, we have evolved from an enzyme manufacturing company to a fully integrated biopharmaceutical enterprise, focused on healthcare. We apply our proprietary fermentation technologies to develop innovative and effective biomolecules in diabetology, oncology, cardiology and other therapeutic segments. At Biocon, our success has been our ability to develop innovative technologies and products and to rapidly leverage them to adjacent domains. This unique "integrated innovation" approach has yielded a host of patented products and technologies that have enabled multi-level relationships with our global clientele.

Location

1406, Woodbridge Commons
Iselin
New Jersey
08830
United States of America

Contact

Phone: 732 636 2950
Fax: 732 636 2951
Email: sandeep.rao@bioconusa.com


News Articles [43 Associated News Articles listed on BioPortfolio]

FDA Approves Mylan and Biocon’s Fulphila, the First Biosimilar to Neulasta

HERTFORDSHIRE, England and PITTSBURGH and BENGALURU, India, June 4, 2018/PRNewswire/ — Mylan N.V. (NASDAQ: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the U....

Biocon down 5% on manufacturing woes

Indian drugmaker Biocon closed more than 5% down at 628.65 rupees after trading on Mumbai on Thursday.

Mylan, Biocon Receive MAA

Mylan and Biocon announced that their co-developed biosimilar insulin glargine Semglee has received marketing authorization approval from the European Commission following the positive recommendation ...

Mylan, Biocon's Neulasta biosimilar OK'd by FDA

Fulphila, or pegfilgrastim-jmdb, from Mylan and Biocon was approved by the FDA to treat patients with non-myeloid cancer unde -More- 

Mylan and Biocon’s biosimilar to neulasta gains FDA approval

Mylan and Biocon have secured the US Food and Drug Administration’s (FDA) approval for their fulphila, which is a biosimilar...Read More... The post Mylan and Biocon’s biosimilar to neulasta g...

Biocon consolidated net up by 3% in Q4 to Rs.153 Cr, dividend of 20%

Biocon, a Rs.4,100 crore leading innovation─led bio─pharmaceutical company from Bengaluru, has posted small growth of 3 per cent in consolidated net profit during the fourth quarter ended March 20...

Biocon and Mylan win EU and Australian approval for biosimilar insulin glargine

Netherlands-incorporated Mylan and Indian development partner Biocon have been granted European approval…

U.S. FDA Approves Fulphila (pegfilgrastim-jmdb), the First Biosimilar to Neulasta

HERTFORDSHIRE, England and PITTSBURGH and BENGALURU, India, June 4, 2018 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the U.S. Food and...

Drugs and Medications [0 Results]

None

PubMed Articles [2 Associated PubMed Articles listed on BioPortfolio]

Biocon's target factory.

Promising effect of rapamycin on multiple sclerosis.

The routine therapies for relapsing-remitting multiple sclerosis (RRMS) are common disease-modifying medications, yet are not effective in all patients. The aim of the present clinical trial was to ev...

Clinical Trials [0 Results]

None

Companies [6 Associated Companies listed on BioPortfolio]

Biocon Limited

Established in 1978, Biocon Limited is India's largest biotechnology Company by revenue. The Group, promoted by Ms. Kiran Mazumdar-Shaw, is a fully-integrated, innovation-driven h...

BioCon Valley® GmbH

Born out of Germany´s "BioRegio" competition in 1996 BioCon Valley represents an interdisciplinary network in the field of modern life sciences and health care.Universities, research and health care ...

Biocon

Biocon is India's leading biotechnology enterprise. Over the past 25 years, we have evolved from an enzyme manufacturing company to a fully integrated biopharmaceutical enterprise, focused on healthca...

BIOCON, INC.

Since 1978 BIOCON has provided highly reliable, custom small animal research services to the region’s leading biomedical scientists. Whether your study involves small animal housing, breeding and co...

Biocon Ltd

More Information about "Biocon" on BioPortfolio

We have published hundreds of Biocon news stories on BioPortfolio along with dozens of Biocon Clinical Trials and PubMed Articles about Biocon for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Biocon Companies in our database. You can also find out about relevant Biocon Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Enzymes
Enzymes are proteins that catalyze (i.e., increase the rates of) chemical reactions. In enzymatic reactions, the molecules at the beginning of the process, called substrates, are converted into different molecules, called products. Almost all chemical re...

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...


Corporate Database Quicklinks



Searches Linking to this Company Record